ReviewAnesthesiology2011
Genetic variation, β-blockers, and perioperative myocardial infarction.
Review in Anesthesiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Clinical pharmacology and therapeutics · 2013Pooled it
- Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial.Drug design, development and therapy · 2018Trial
- Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP.Anesthesia and analgesia · 2017Trial
- Profiling metoprolol enantiomers in urine of hypertensive patients.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Enantioselective analysis of metoprolol in plasma of hypertensive patients undergoing long-term therapy: Insights for personalized medicine.BioImpacts : BI · 2025Article
- The role of plasma concentrations and drug characteristics of beta-blockers in fall risk of older persons.Pharmacology research & perspectives · 2023Article
- Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report.The American journal of case reports · 2023Article
- Longitudinal data analysis for rare variants detection with penalized quadratic inference function.Scientific reports · 2017Article
- Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population.Patient preference and adherence · 2016Article
- GNAS gene variants affect β-blocker-related survival after coronary artery bypass grafting.Anesthesiology · 2014Observational
- Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery.American heart journal · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Perioperative myocardial infarction is a common and potentially fatal complication after noncardiac surgery, particular among patients with cardiovascular risk factors. β-blockers have been considered a mainstay in prevention and treatment of perioperative myocardial infarction, yet recent evidence suggests that β-blockers may have an unfavorable risk profile in this setting, and the use has become controversial. What seems conspicuously absent from the current discussion is the appreciation of how much interindividual genetic variation influences the clinical response to β-blocker therapy. Genetic variation in the adrenergic signaling pathway is common, and has a major impact on adrenergic receptor function and β-blocker efficacy in other cardiovascular diseases, such as heart failure and hypertension. Genetic variation in the cytochrome P450 2D6, or CYP2D6, enzyme, which is responsible for the metabolism of most β-blockers, is also important and can lead to poor metabolizing of β-blockers (potential toxicity) or their ultra-rapid degradation (decreased efficacy). Here, we review the molecular, cellular, and physiologic consequences of polymorphisms in the adrenergic signaling pathway and CYP2D6 gene, and show that these are likely relevant factors influencing efficacy, safety, and toxicity of β-blocker therapy in prevention and treatment of perioperative myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.